A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.
from Cancer Information - Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer
0 коммент.